Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC for Mucositis in Head and Neck Cancer
NCT03982537Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of acetylcysteine in mucositis (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Reduction in Severe Mucositis with Pre-treatment N-acetyl cysteine. Planned start Jun 2020; status: withdrawn.
02
Drugs
acetylcysteine
03
Conditions
mucositis
Beyond the preview
Go deeper on NCT03982537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982537.